Literature DB >> 21151855

Taxane pathway.

Connie Oshiro1, Sharon Marsh, Howard McLeod, Michelle Whirl Carrillo, Teri Klein, Russ Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 21151855      PMCID： PMC2998989          DOI： 10.1097/FPC.0b013e3283335277

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  66 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Mutational analysis of the beta-tubulin gene in lung cancer.

Authors:  Junji Tsurutani; Takefumi Komiya; Hisao Uejima; Hirohito Tada; Negoro Syunichi; Mikio Oka; Shigeru Kohno; Masahiro Fukuoka; Kazuhiko Nakagawa
Journal:  Lung Cancer       Date:  2002-01       Impact factor: 5.705

3.  Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients.

Authors:  Verena Materna; Paweł Surowiak; Irina Kaplenko; Merek Spaczyński; Zhenfeng Duan; Maciej Zabel; Manfred Dietel; Hermann Lage
Journal:  Virchows Arch       Date:  2007-02       Impact factor: 4.064

4.  beta-Tubulin mutations in ovarian cancer using single strand conformation analysis-risk of false positive results from paraffin embedded tissues.

Authors:  Henrik Gréen; Per Rosenberg; Peter Söderkvist; György Horvath; Curt Peterson
Journal:  Cancer Lett       Date:  2005-07-05       Impact factor: 8.679

Review 5.  Clinical pharmacokinetics of docetaxel.

Authors:  S J Clarke; L P Rivory
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

6.  Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.

Authors:  M Monzó; R Rosell; J J Sánchez; J S Lee; A O'Brate; J L González-Larriba; V Alberola; J C Lorenzo; L Núñez; J Y Ro; C Martín
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

7.  Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.

Authors:  Tristan M Sissung; Klaus Mross; Seth M Steinberg; Dirk Behringer; William D Figg; Alex Sparreboom; Stephan Mielke
Journal:  Eur J Cancer       Date:  2006-09-06       Impact factor: 9.162

8.  Variability in human cytochrome P450 paclitaxel metabolism.

Authors:  D S Sonnichsen; Q Liu; E G Schuetz; J D Schuetz; A Pappo; M V Relling
Journal:  J Pharmacol Exp Ther       Date:  1995-11       Impact factor: 4.030

9.  Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver.

Authors:  M Shou; M Martinet; K R Korzekwa; K W Krausz; F J Gonzalez; H V Gelboin
Journal:  Pharmacogenetics       Date:  1998-10

10.  Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study.

Authors:  Hee Seung Kim; Mi-Kyung Kim; Hyun Hoon Chung; Jae Weon Kim; Noh Hyun Park; Yong Sang Song; Soon Beom Kang
Journal:  Gynecol Oncol       Date:  2009-02-08       Impact factor: 5.482
View more
  18 in total

1.  Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancer.

Authors:  Joel L Weissfeld; Brenda Diergaarde; Tomoko Nukui; Shama Buch; Arjun Pennathur; Mark A Socinski; Jill M Siegfried; Marjorie Romkes
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609

2.  Structural Characterization of Anticancer Drug Paclitaxel and Its Metabolites Using Ion Mobility Mass Spectrometry and Tandem Mass Spectrometry.

Authors:  Hong Hee Lee; Areum Hong; Yunju Cho; Sunghwan Kim; Won Jong Kim; Hugh I Kim
Journal:  J Am Soc Mass Spectrom       Date:  2016-02       Impact factor: 3.109

3.  Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.

Authors:  Stephanie N Dorman; Katherina Baranova; Joan H M Knoll; Brad L Urquhart; Gabriella Mariani; Maria Luisa Carcangiu; Peter K Rogan
Journal:  Mol Oncol       Date:  2015-08-22       Impact factor: 6.603

4.  PharmGKB: the Pharmacogenomics Knowledge Base.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Methods Mol Biol       Date:  2013

Review 5.  Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology.

Authors:  Rachael R Schulte; Richard H Ho
Journal:  Mol Pharmacol       Date:  2019-02-19       Impact factor: 4.436

6.  Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.

Authors:  Delisha A Stewart; Jason H Winnike; Susan L McRitchie; Robert F Clark; Wimal W Pathmasiri; Susan J Sumner
Journal:  J Proteome Res       Date:  2016-08-03       Impact factor: 4.466

7.  Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.

Authors:  Heather E Wheeler; Eric R Gamazon; Claudia Wing; Uchenna O Njiaju; Chidiamara Njoku; Robert Michael Baldwin; Kouros Owzar; Chen Jiang; Dorothy Watson; Ivo Shterev; Michiaki Kubo; Hitoshi Zembutsu; Eric P Winer; Clifford A Hudis; Lawrence N Shulman; Yusuke Nakamura; Mark J Ratain; Deanna L Kroetz; Nancy J Cox; Mary Eileen Dolan
Journal:  Clin Cancer Res       Date:  2012-11-30       Impact factor: 12.531

8.  Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.

Authors:  Stefanie D Krens; Howard L McLeod; Daniel L Hertz
Journal:  Pharmacogenomics       Date:  2013-04       Impact factor: 2.533

9.  A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.

Authors:  Christine H Chung; Michelle A Rudek; Hyunseok Kang; Shanthi Marur; Pritish John; Nancy Tsottles; Sarah Bonerigo; Andy Veasey; Ana Kiess; Harry Quon; Anthony Cmelak; Barbara A Murphy; Jill Gilbert
Journal:  Oral Oncol       Date:  2015-12-17       Impact factor: 5.337

10.  Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study.

Authors:  Tulay Kus; Gokmen Aktas; Gokay Alpak; Mehmet Emin Kalender; Alper Sevinc; Seval Kul; Mithat Temizer; Celaletdin Camci
Journal:  Support Care Cancer       Date:  2015-11-07       Impact factor: 3.359
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.